Strong, but age-dependent, protection elicited by a deoxyribonucleic acid/modified vaccinia Ankara simian immunodeficiency virus vaccine

Open Forum Infectious Diseases

Volumn 3, Issue 1, 2016, Pages

  Chamcha, Venkateswarlu ^a   Kannanganat, Sunil ^a   Gangadhara, Sailaja ^a   Nabi, Rafiq ^b   Kozlowski, Pamela A ^b   Montefiori, David C ^c   LaBranche, Celia C ^c   Wrammert, Jens ^d   Keele, Brandon F ^e   Balachandran, Harikrishnan ^f   Sahu, Sujata ^f   Lifton, Michelle ^f   Santra, Sampa ^f   Basu, Rahul ^g   Moss, Bernard ^h   Robinson, Harriet L ^g   Amara, Rama Rao ^a  

^a EMORY UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g Research and Development   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Age dependent protection; Antibody; DNA MVA vaccine; HIV vaccine; SIV

Indexed keywords

DNA MODIFIED VACCINIA ANKARA HUMAN IMMUNODEFICIENCY VIRUS VACCINE; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; POL PROTEIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRAMESHIFT MUTATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INFECTION RISK; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; RNA SPLICING; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 85000717961     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw034     Document Type: Article

References (41)

1. Smith JM, Amara RR, McClure HM, et al. Multiprotein HIV-1 clade B DNA/MVA vaccine: construction, safety, andimmunogenicity in Macaques. AIDS Res Hum Retroviruses 2004; 20:654-65.
2. Wyatt LS, Belyakov IM, Earl PL, et al. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008; 372:260-72.
3. Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610-9.
4. Goepfert PA, Elizaga ML, Seaton K, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2014; 210:99-110.
5. Lai L, Kwa S, Kozlowski PA, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011; 204:164-73.
6. Yeh WW, Rao SS, Lim SY, et al. The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. J Virol 2011; 85:10389-98.
7. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011; 3:81ra36.
8. Reynolds MR, Sacha JB, Weiler AM, et al. The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J Virol 2011; 85:9637-40.
9. Smith JM, Amara RR, Campbell D, et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 2004; 20:1335-47.
10. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24.
11. Van Rompay KK, Greenier JL, Cole KS, et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol 2003; 77:179-90.
12. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by simian immunodeficiency virus smE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117-34.
13. Kwa S, Sadagopal S, Shen X, et al. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection. J Virol 2015; 89:4690-5.
14. Lai L, Vodros D, Kozlowski PA, et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV- 89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007; 369:153-67.
15. Kozlowski PA, Lynch RM, Patterson RR, et al. Modified wick method usingWeck- Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 2000; 24:297-309.
16. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R, eds. Current Protocols in Immunology. New York: JohnWiley and Sons. Curr Protoc Immunol. 2005. Jan;Chapter 12:Unit 12.11. doi: 10.1002/0471142735.im1211s64.
17. Silveira EL, Kasturi SP, Kovalenkov Y, et al. Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies. J Immunol Methods 2015; 416:69-83.
18. Ackerman ME, Moldt B, Wyatt RT, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 2011; 366:8-19.
19. Alpert MD, Heyer LN, Williams DE, et al. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 2012; 86:12039-52.
20. Hulot SL, Cale EM, Korber BT, Letvin NL. Vaccine-induced CD8+ T lymphocytes of rhesus monkeys recognize variant forms of an HIV epitope but do not mediate optimal functional activity. J Immunol 2011; 186:5663-74.
21. Hudgens MG, Gilbert PB, Mascola JR, et al. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J Infect Dis 2009; 200:609-13.
22. Hudgens MG, Gilbert PB. Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics 2009; 65:1223-32.
23. Kirmaier A, Wu F, Newman RM, et al. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010; 8:e1000462.
24. Reynolds MR, Weiler AM, Piaskowski SM, et al. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol 2011; 84:9190-9.
25. Weinberger B, Herndler-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46:1078-84.
26. Fulton RB, Varga SM. Effects of aging on the adaptive immune response to respiratory virus infections. Aging health 2009; 5:775.
27. Dunn-Walters DK, Ademokun AA. B cell repertoire and ageing. Curr Opin Immunol 2010; 22:514-20.
28. Frasca D, Landin AM, Riley RL, Blomberg BB. Mechanisms for decreased function of B cells in aged mice and humans. J Immunol 2008; 180:2741-6.
29. Zheng B, Switzer K, Marinova E, et al. Correction of age-associated deficiency in germinal center response by immunization with immune complexes. Clin Immunol 2007; 124:131-7.
30. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7.
31. Burton SL, Kilgore KM, Smith SA, et al. Breakthrough ofsimian immunodeficiency virus strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proc Natl Acad Sci U S A 2015; 112:10780-5.
32. Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccineelicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009; 182:3718-27.
33. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with simian immunodeficiency virus SIV(mac251). J Immunol 2005; 174:2185-9.
34. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009; 83:791-801.
35. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010; 84: 7161-73.
36. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization- resistant simian immunodeficiency virus challenges in rhesus monkeys. Nature 2012; 482:89-93.
37. Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87:1708-19.
38. Barouch DH, Alter G, Broge T, et al. HIV-1 vaccines. Protective efficacy of adenovirus/ protein vaccines against SIV challenges in rhesus monkeys. Science 2015; 349:320-4.
39. Fouts TR, Bagley K, Prado IJ, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A 2015; 112: E992-9.
40. Richmond JF, Lu S, Santoro JC, et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998; 72:9092-100.
41. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.